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NOVA1 induction by inflammation 
and NOVA1 suppression by 
epigenetic regulation in head and 
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Neuro-oncological ventral antigen 1 (NOVA1) is known as a neuron-specific pre-mRNA binding splicing 
factor. Previously, it was shown to be highly upregulated in T lymphocytes, as well as fibroblasts/
stromal spindle cells, in tertiary lymphoid tissues formed by the benign immune-inflammatory 
process, while it was frequently downregulated in tumor cells and other cells within the tumor 
microenvironment. Here, we sought to identify the mechanisms of NOVA1 modulation in head and 
neck squamous cell carcinoma (HNSCC). NOVA1 was induced by inflammatory-immune signals within 
the tumor microenvironment and was suppressed by epigenetic dysregulation, such as that with 
miR-146. We found attenuated expression of NOVA1 to be associated with non-oropharynx sites 
such as oral cavity, hypopharynx, and larynx, human papilloma virus (HPV)-negative SCC defined 
by immunohistochemistry for p16INK4a expression, fewer tumor infiltrating lymphocytes, and poor 
patient outcomes. Moreover, changes were discovered in epithelial mesenchymal transition-associated 
markers according to NOVA1 status. This study provides some insights to the underlying mechanism 
of NOVA1 regulation and suggests that NOVA1 may serve as a prognostic biomarker and potential 
therapeutic target for HNSCC in the future.
Neuro-oncological ventral antigen 1 (NOVA1) is a neuron-specific pre-mRNA binding splicing factor and is 
necessary for the development of the motor system and the survival of motor neurons. Recent studies have shown 
that NOVA1 is enriched in normal fibroblasts and activated T cells1–5 and plays a role in various cancers6–8. 
Through our research, we have discovered that NOVA1 is strongly expressed in most fibroblasts/stromal spindle 
cells and in only a small number of T lymphocytes within normal physiologic secondary lymphoid tissue; mean-
while, it appears to be highly upregulated in T lymphocytes, as well as fibroblasts/stromal spindle cells, in ter-
tiary lymphoid tissues formed by benign immune-inflammatory processes, such as Helicobacter pylori-associated 
gastritis. Within the tumor microenvironment of gastric cancers, we have observed progressive loss of NOVA1 
expression in T lymphocytes, stromal spindle cells, and tumor cells with more advanced stages of gastric cancer 
and have found decreased NOVA1 expression in these cells to be related to poor patient prognosis. Also, we have 
reported that miR-146b-5p may target NOVA1 and may lead to NOVA1 suppression9–11. Meanwhile, through 
preliminary experiments, we have discovered that NOVA1 is highly expressed in both tumor cells and microen-
vironment cells in human papilloma virus (HPV)-related oropharyngeal squamous cell carcinoma (SCC), but 
decreased in HPV-negative head and neck squamous cell carcinoma (HNSCC) (Supplementary Fig. S1). These 
findings suggest that inflammatory and immune reactions in response to HPV infection might be involved in the 
induction of NOVA1 within the tumor microenvironment.
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According to comprehensive genetic analyses using The Cancer Genome Atlas Network (TCGA, https://can-
cergenome.nih.gov) and the Catalogue Of Somatic Mutations in Cancer (COSMIC, http://cancer.sanger.ac.uk/
cosmic), genetic mutations and epigenetic hypermethylation eliciting NOVA1 dysregulation appear to be rare 
in most cancers. Despite marked variations in expression levels of NOVA1 in HNSCC, recent comprehensive 
studies have revealed that genetic alteration of NOVA1 is very rare, at a frequency of about 2% (Supplementary 
Fig. S2). From this and our previous study11, we conjectured that epigenetic regulation, specifically with microR-
NAs (miRNA), may be involved in the dysregulation of NOVA1 in HNSCC.
In the present study, we sought to determine whether NOVA1 is induced by inflammatory signals and epige-
netically suppressed within the tumor microenvironment in HNSCC.
Results
NOVA1 expression in tumor cells upon HPV E6/E7 transfection. Western blot analysis revealed 
NOVA1 expression in FaDu cells, but not in CAL27 cells. While p1321 HPV-16 E6/E7 plasmid was successfully 
transfected into FaDu and CAL27 cells (Supplementary Fig. S3), it did not induce a significant change in NOVA1 
protein levels (Fig. 1A and Supplementary Fig. S4). Real-time PCR analysis of NOVA1 mRNA expression gener-
ally showed no significant changes therein upon transfection of HPV-16 E6/E7 genes into FaDu and CAL27 cells, 
although there was a slight increase in NOVA1 mRNA after 24 hours of transfection into FaDu cells (Fig. 1B).
NOVA1 induced by poly(dA:dT) and suppressed by miR-146. Endogenous expression levels of 
predicted target miRs, including hsa-miR-146a-5p, -146b-5p, -181a, -181b, -181c, -181d, -27a, and -27b, were 
compared among the HPV-negative non-oropharynx SCC cell lines FaDu and CAL27 and the HPV-positive 
oropharynx SCC cell line UMSCC47 (Supplementary Fig. S5). FaDu cells, which endogenously express NOVA1, 
exhibited greater expression of these miRs, especially miR-146a-5p and miR-146b-5p, compared to CAL27 cells, 
which showed very low NOVA1 expression (Fig. 2A).
After 24 hour-transfection of poly(dA:dT) double-stranded DNA into FaDu cells, a dose-dependent increase 
in NOVA1 expression was noted (Fig. 2B). Confirming the suppressive effect of miR-146b on NOVA1, FaDu 
cells showed decreased NOVA1 expression after 24 hours of transfection with miR-146b mimic (Fig. 2C; 
scramble versus miR-146b mimic; p < 0.001). Transfecting inhibitors of miR-146b (anti-miR-146b-5p or 
anti-miR-146b-3p) only slightly increased NOVA1 levels in FaDu cells; the difference was not statistically sig-
nificant (scramble versus anti-miR-146b-5p, p = 0.106; scramble versus anti-miR-146b-3p, p = 0.067; Fig. 2C). 
Meanwhile, both treatment with poly(dA:dT) alone and treatment with poly(dA:dT) and anti-miR-146b-5p or 
poly(dA:dT) and anti-miR-146b-3p significantly increased NOVA1 expression in FaDu cells (Fig. 2C; scramble 
Figure 1. NOVA1 expression after transfection of plasmid p1321 HPV-16 E6/E7. (A) In Western blot analysis, 
NOVA1 protein expression was detected in FaDu cells, but not in CAL27 cells. Transfection of HPV type 16 
E6/E7 genes into FaDu and CAL27 did not induce a significant change in NOVA1 protein expression. (B) 
Generally, no significant changes in NOVA1 mRNA expression were observed upon transfection of HPV-16 E6/
E7 genes into FaDu and CAL27 cells; a slight increase in mRNA was noted after 24 hours of transfection into 
FaDu cells. Fold changes in NOVA1 mRNA values were calculated based on NOVA1 levels of FaDu-CTR at 24 h 
and 48 h. Compared to NOVA1 mRNA levels in FaDu cells, those in CAL27 cells were very low. (CTL, controls 
with transfected empty vector; pHPV, cells with transfected plasmid HPV-16 E6/E7).
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versus poly(dA:dT) + scramble; p = 0.004; scramble versus poly(dA:dT) + anti-miR-146b-5p, p = 0.001; scramble 
versus poly(dA:dT) + anti-miR-146b-3p, P = 0.014; anti-miR-146b-5p versus poly(dA:dT) + anti-miR-146b-5p, 
p = 0.015; anti-miR-146b-3p versus poly(dA:dT) + anti-miR-146b-3p, p = 0.041). Treatment with miR-146b 
mimic alone however, did not significantly increase NOVA1 levels above treatment with miR-146b mimic and 
poly(dA:dT) in FaDu cells (Fig. 2C; miR-146b mimic versus poly(dA:dT) + miR-146b mimic, p = 0.305). Overall, 
NOVA1 levels were the lowest when treating FaDu cells with miR-146b mimic and highest when treating FaDu 
cells with poly(dA:dT) + anti-miR-146b-5p.
Expression of miR-146 and NOVA1 in tumor and microenvironment cells in HNSCC tissue sam-
ples. In HNSCC samples from 50 randomly selected patients, hsa-miR-146a-5p and -146b-5p were investi-
gated in tumor and adjacent stromal areas. General expression levels of miRs, especially miR-146a, were higher 
in tumor areas than in stromal areas (Fig. 3A). MiR levels in tumor and stroma tissue were positively correlated, 
although the correlation strength was fair (has-miR-146a-5p, r = 0.418, p = 0.003; has-miR-146b-5p, r = 0.308, 
p = 0.003; Fig. 3B).
NOVA1 expression varied in tumor cells and lymphocytes and stromal spindle cells from the tissue microen-
vironment of 396 HNSCC specimens. Attenuated NOVA1 expression, which showed an H-score < 200 and indi-
cated a loss of NOVA1 in more than one-third of the cell population, was more frequent in tumor cells than in 
lymphocytes and stromal spindle cells (Fig. 3C and Supplementary Fig. S6). Generally, NOVA1 expression status 
in tumor cells was correlated with that of T lymphocytes and stromal spindle cells (tumor cells and T lympho-
cytes, r = 0.769, p < 0.001; tumor cells and stromal spindle cells, r = 0.753, p < 0.001; Fig. 3D).
NOVA1 expression in association with anatomical sites, HPV infection status, T cell infiltra-
tion, epithelial mesenchymal transition markers, and patient outcomes. Attenuated expres-
sion (H-score < 200) of NOVA1 in tumor cells was frequent in non-oropharynx SCC such as SCC arising in 
oral cavity, hypopharynx, larynx, and p16 (HPV)-negative SCC (p < 0.001, respectively; Fig. 4A,B), and it was 
most frequently observed in p16-negative non-oropharynx SCC, when comparing oropharynx SCC and/or 
HPV-positive cases (p < 0.001; Fig. 4C). Regarding TILs, which are observed within tumor cell nests, specimens 
Figure 2. Endogenous and post-transfection expression levels of NOVA1. (A) Endogenous expression of 
NOVA1 protein and predicted target miRs in the HPV-negative non-oropharynx SCC cell lines FaDu and 
CAL27 and the HPV-positive oropharynx SCC cell line UMSCC47. FaDu cells show the highest endogenous 
expression levels of NOVA1, miR-146a-5p, and miR-146b-5p. Fold changes in each molecule were calculated 
in comparison to UMSCC47. (B) After 24 hours of transfection of poly(dA:dT) double-stranded DNA in 
FaDu cells, a dose-dependent increase in NOVA1 expression was noted. (C) After 24-hour transfection into 
FaDu cells, NOVA1 levels were the lowest when treating with miR-146b mimic, but the highest when treating 
with poly(dA:dT) + anti-miR-146b-5p. When treating with miR-146b mimic, adding poly(dA:dT) did not 
significantly increase NOVA1 expression. Fold changes in NOVA1 were calculated in comparison to cells 
treated with scramble.
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showing attenuated NOVA1 expression in tumor cells showed lower cell densities of CD3+ or CD8+ TILs than 
those showing strong NOVA1 expression (Fig. 4D). A marker of epithelial mesenchymal transition (EMT), Twist 
expression in tumor cells was related to NOVA1 expression status in tumor cells, but not to NOVA1 status in 
stromal spindle cells/fibroblasts or T lymphocytes (Fig. 4E; Supplementary Fig. S7). SNAI1/SLUG expression 
(another marker of EMT) in tumor cells was related to NOVA1 expression status in T lymphocytes and stromal 
spindle cells/fibroblasts, but not to NOVA1 status in tumor cells (Fig. 4F; Supplementary Fig. S7).
Regarding associations with patient outcomes, attenuated NOVA1 expression in tumor cells was associated 
with inferior OS (Fig. 4G, p = 0.018) and PFS in Kaplan-Meier analysis (Fig. 4H, p = 0.030). In multivariate Cox 
regression analysis, attenuated NOVA1 expression in tumor cells was identified as an independent poor prog-
nostic factor for OS (Hazard ratio = 2.104, p = 0.005) and PFS (Hazard ratio = 1.599, p = 0.03), as were other 
clinicopathologic factors, such as older age, non-oropharynx site, advanced pathologic T stage (pT stage 3–4), 
advanced pathologic N stage (pN stage 2–3), and lower cell density of tumor infiltrating CD8 + cytotoxic T cells 
(Supplementary Tables S5 and S6).
Microenvironment Cell Populations-counter analysis. Microenvironment Cell Populations-counter 
(MCP-counter) analysis using a gene set for HNSCC generated from TCGA (https://cancergenome.nih.gov, 
n = 348) indicated that high NOVA1 expression is significantly correlated with greater abundance of immune 
cells, including T cells, CD8+ T cells, cytotoxic lymphocytes, NK cells, B cells, monocytes, and myeloid dendritic 
cells, as well as stromal cells of fibroblasts and endothelial cells. Upregulation of the CD8+ T cell-related genes 
CD8A and CD8B was significantly related to high NOVA1 expression (Fig. 5; Supplementary Table S7), as were 
upregulation of TWIST and SNAI1 and downregulation of SNAI2 (SLUG) and TGFB1 (Fig. 5; Supplementary 
Table S8). In summary, lower abundances of immune and stromal cells, downregulation of CD8+ T cell-related 
genes, downregulation of TWIST and SNAI1, and upregulation of SNAI2 and TGFB1 were all found to be related 
to low NOVA1 expression (Fig. 5; Supplementary Tables S7 and S8; Supplementary Fig. S8).
Figure 3. Expression of miR-146 and NOVA1 in tumor cells and microenvironment cells from HNSCC tissue 
samples. (A) Expression of miR-146 in tumor areas (T) and stromal areas (S) of HNSCC tissue samples (n = 50). 
General expression levels of miRs, especially miR-146a, were higher in tumor areas than in stromal areas. (B) 
Levels of miR-146 in tumor and stroma areas were positively correlated. (C) Attenuated NOVA1 expression, 
reflected as an H-score < 200, indicating loss of NOVA1 in more than one-third of cells, were more frequently 
observed in tumor cells than in lymphocytes and stromal spindle cells. (D) Generally, tumor NOVA1 expression 
status was correlated with that of T lymphocytes and stromal spindle cells (P < 0.001, respectively).
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Discussion
In the present study, we first sought to determine whether NOVA1 is induced in tumor cells by inflammatory 
signals within the microenvironment of HNSCC. Oropharynx SCC arises within lymphoid and immune cell-rich 
Figure 4. NOVA1 expression in association with anatomical sites, HPV infection status, T cell infiltration, 
EMT markers, and patient outcomes. (A,B) Attenuated NOVA1 expression (H-score < 200) in tumor cells was 
more frequent in non-oropharynx SCC and p16 (HPV)-negative SCC (P < 0.001, respectively). (C) Attenuated 
expression of NOVA1 in tumor cells was most frequently observed in p16-negative non-oropharynx SCC 
(P < 0.001). (D) Specimens showing attenuated NOVA1 among tumor cells showed lower levels of CD3+ or 
CD8+ TILs than those with strong NOVA1 expression. Average cell numbers of T lymphocytes were counted 
at x400 magnification (x400 HPF). (E) Twist expression was higher in tumor cells from specimens with high 
NOVA1 expression. (F) SNAI1/SLUG expression in tumor cells showed significant differences according to 
NOVA1 expression status in T lymphocytes and stromal spindle cells. (G,H) Attenuated NOVA1 expression in 
tumor cells was associated with inferior overall survival and progression-free survival rates.
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microenvironments (palatine tonsils and base of the tongue) and is primarily associated with HPV infection. 
Non-oropharynx SCC such as SCC of oral cavity, hypopharynx, and larynx, however, arises from an immune 
cell-poor tissue microenvironment and is generally unrelated to HPV infection. Although the lymphoid and 
immune cell structures of the oropharynx are physiologically formed as secondary lymphoid structures, inflam-
matory stimuli in response to HPV infection are thought to induce NOVA1 expression in tumor cells and the 
surrounding microenvironment. Nonetheless, in non-oropharynx SCC, NOVA1 could still be induced in tumor 
cells and the surrounding microenvironment upon formation of tertiary lymphoid structures within the tumor 
microenvironment as an immune response to tumor growth12–16. As expected, in the present study, most oro-
pharynx SCCs showed strong NOVA1 expression in tumor cells, while non-oropharynx SCC frequently showed 
attenuated expression. Likewise, HPV (p16 immunohistochemistry)-positive SCC mostly exhibited strong 
NOVA1 expression, while HPV-negative SCC frequently showed attenuated expression in tumor cells. Such high 
NOVA1 expression in oropharynx SCC may be related to an abundance of lymphoid structures within the tissue 
microenvironment.
As stated above, most oropharynx SCCs show HPV positivity. Thus, immune reactions within the lymphoid 
structures, which are activated by HPV infection, might stimulate NOVA1 induction. HPV type 16 is the most 
prevalently detected virus type in HPV-mediated oropharynx SCC, accounting for about 80% of all HPV-positive 
SCC cases, and HPV E6 and E7 are the most potent oncogenes affecting the tumorigenesis of HPV-mediated 
tumors17. In the present study, transfection of HPV 16 E6/E7 genes to originally HPV-negative SCC cells did not 
significantly induce NOVA1 in tumor cells. Accordingly, we deemed that HPV infection, triggering immune 
reactions within the surrounding microenvironment, is only indirectly involved in NOVA1 induction.
As a limitation of our study, a single tumor cell line could not fully represent actual tissue conditions, com-
prising activated inflammatory and lymphoid structures formed within the tissue microenvironment. To address 
this limitation, we sought to simulate immune signals by treating cells with poly(dA: dT). Transfected poly(dA: 
dT) is recognized by several cytosolic DNA sensors, activates immune responses, and triggers the formation of 
the inflammasome18–21. Indeed, by mimicking inflammatory signals, poly(dA:dT) upregulated NOVA expression 
in the present study. In line with this result, we noted higher infiltrating cell densities of CD3+ T lymphocytes 
and CD8+ cytotoxic T lymphocytes in HNSCC specimens showing strong NOVA1 expression among tumor 
cells, compared to specimens showing attenuated NOVA1 expression. MCP-counter analysis using gene sets for 
HNSCC from TCGA also indicated that high NOVA1 expression may be related to increases in immune cells, 
Figure 5. Microenvironment Cell Populations-counter analysis. Z-score transformed values of log2 
(normalized rsem + 1) values of genes and MCP-counter values were used to identify differences between 
groups for cell type abundance, inflammation-related genes, and EMT-related genes. Lower quantities of 
immune cells and stromal cells, downregulation of CD8+ T cell-related genes, and upregulation of SNAI2 and 
TGFB1 were related to low NOVA1 expression.
7Scientific RepoRtS |         (2019) 9:11231  | https://doi.org/10.1038/s41598-019-47755-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
such as CD8+ T cells, and stromal cells, such as fibroblasts. Overall, these findings support our hypothesis that 
inflammatory and immune signals within the microenvironment may induce NOVA1 upregulation.
Despite our meaningful results, the biological significance of NOVA1 upregulation in cancer remains uncer-
tain. To identify possible roles for NOVA beyond its known role as a neuron-specific pre-mRNA binding splicing 
factor, we focused on EMT, since NOVA1 upregulation seems to occur by interacting with microenvironment 
inflammatory signals and since NOVA1 is known to be enriched in normal fibroblasts5. In HNSCC tissue sam-
ples, we found Twist and SNAI1 expression (EMT markers) to be related to NOVA1 status in tumor cells, as 
well as stromal spindle cells and T lymphocytes. Moreover, MCP-counter analysis using the gene set of HNSCC 
from TCGA also indicated that NOVA1 expression is related to upregulation or downregulation of EMT signa-
ture genes, including SNAI1, TWIST, SNAI2, and TGFB1. Although further studies of direct signal pathways are 
needed, these findings suggest that changes in NOVA1 expression in tumor cells or the tissue microenvironment 
may affect EMT and that NOVA1 may act as a signaling factor between tumor cells and interacting stromal cells.
Regarding the clinical implications of NOVA1 in HNSCC, we discovered that attenuated NOVA1 expression 
in tumor cells is related to poor patient prognosis via univariate and multivariate survival analysis. This suggests 
that NOVA1 suppression might be related to an aggressive cancer cell phenotype. As a mechanism of NOVA1 
suppression, we suspected that epigenetic regulations could affect genetically normal lymphocytes and stromal 
spindle cells. Several studies have found that altered miRNA expression likely occurs in the tumor microenviron-
ment as the result of crosstalk among stromal spindle cells and immune cells through various signaling autocrine 
and/or paracrine methods22. In HNSCC tissue samples, we noted that variable expression of hsa-miR-146a-5p 
and miR-146b-5p, which are predicted to target NOVA1, was positively correlated between tumor and stromal 
areas: the expression levels of individual miRs were relatively higher in tumor areas than in stromal areas, sug-
gesting that a major source of upregulated miRs may be tumor cells. To confirm NOVA1 inhibition by miRs in 
vitro, we experimented on FaDu cells, because this cell line shows higher expression of miR-146 and NOVA1. 
Because the sequences of miR-146a-5p and miR-146b-5p were very similar and their predicted target sites of 
NOVA1 were identical (-AGUUCUC-: Supplementary Fig. S9), transfection experiments were performed with 
miR-146b mimic and anti-miR-146b inhibitors. In doing so, we found that miR-146 (miR-146a and miR-146b) 
could suppress NOVA1 in tumor cells, even in the presence of inflammatory signals simulated by poly(dA:dT) 
transfection. When simultaneously treating cells with poly(dA:dT) and blocking miR-146 with anti-miR-146b-5p 
and anti-miR-146b-3p, NOVA1 expression was increased. From these findings, we discerned that miR-146 may 
be potent suppressors of NOVA1, even in the presence of inflammatory signals. These results could reflect a 
mechanism by which NOVA1 is epigenetically attenuated in tumor cells, even when immune-inflammatory lym-
phoid structures are present, within the tumor microenvironment.
In the process of cancer development and progression, HNSCCs adapt several mechanisms of immune 
escape, such as T cell tolerance, inhibition of inflammatory cytokines, and exhaustion of effective cytotoxic 
T cell function within the tumor microenvironment23–25. In this study, we found that NOVA1 is induced by 
inflammatory-immune signals within the tissue microenvironment and is suppressed by epigenetic dysregula-
tion, potentially by miR-146. Although epigenetic suppression of NOVA1 and impaired immune surveillance 
within the tissue microenvironment according to tumor progression should be investigated further, the present 
study provides some insights into the underlying mechanism of NOVA1 regulation and raises the translational 
potential of NOVA1 as a prognostic biomarker and therapeutic target for HNSCC in the future.
Methods
Cell lines and culture conditions. In the present study, the HPV-negative HNSCC cell lines FaDu (ATCC® 
HTB-43™, pharynx SCC) and CAL27 (ATCC® CRL-2095™, tongue SCC) were used. As a HPV-positive orophar-
ynx SCC cell line, UMSCC47 (ATCC® CRL-3239™, base of tongue SCC) was used. FaDu cells were maintained 
in RPMI-1640 medium (22400-089, Gibco; Life Technologies, CA, USA) supplemented with 10% FBS (6000-
044, Gibco; Life Technologies). CAL27 and UMSCC47 cells were maintained in DMEM medium (SH30243.01, 
HyClone; Thermo Scientific, Logan, UT, USA) supplemented with 10% FBS (6000-044, Gibco; Life Technologies).
Clinical samples. From the database of Severance Hospital Cancer Registry Data, Seoul, South Korea, cases 
of HNSCC were retrieved. Affected anatomical sites included the oropharynx (tonsils, base of tongue, soft palate, 
and oropharynx) and non-oropharynx. Non-oropharyngeal sites included oral cavity (anterior two-thirds of the 
tongue, mouth floor, hard palate, buccal mucosa, and unspecified oral cavity), hypopharynx, larynx (lingual sur-
face of the epiglottis, glottis, supraglottis, subglottis, and larynx), and nasal cavity/paranasal sinuses. Carcinomas 
of nasopharynx, ear cavity, salivary gland, or other anatomical sites were excluded from the present study. 
Formalin-fixed paraffin-embedded tissue (FFPE) specimens from 116 consecutive oropharyngeal SCC and 280 
consecutive non-oropharyngeal SCC patients were included: these patients underwent surgical resection with a 
curative aim from 2005 to 2012 at Severance Hospital Seoul, South Korea. Specimens that underwent decalcifi-
cation were excluded for accurate immunohistochemical analysis. Part of the present cohort had been included 
in our previous studies26–30. Information on various clinical factors, including age at operation, sex, smoking, 
and alcohol consumption, was obtained by reviewing medical records. Pathologic factors, including lympho-
vascular invasion, perineural invasion, pathologic TNM staging according to the 7th American Joint Committee 
on Cancer, and tumor classification by the World Health Organization system31,32, were obtained from slide 
review by three individual pathologists (E.K. Kim, Y.A. Cho, and S.O. Yoon). The median follow-up period was 50 
months (range from 1 to 110 months). Clinicopathologic characteristics are described in Supplementary Table S1. 
This study was approved by the Institutional Review Board of Severance Hospital (Protocol No. 4-2015-0954). A 
written informed consent of the patients was obtained, samples and clinical information were anonymized. All 
experiments were performed in accordance with relevant guidelines and regulations (including all laboratory and 
biosafety regulations).
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Transfection of HPV E6/E7 gene and poly(dA:dT). For transfection of the HPV E6/E7 gene and 
poly(dA:dT), six-well plate polycarbonate membrane transwell inserts (Corning Costar, Cambridge, MA, USA) 
were used. With the TransIT-X2® Dynamic Delivery System (MIR 6000; Cambridge Bioscience, Cambridge, UK), 
we transfected p1321 HPV-16 E6/E7 plasmid (Addgene 292613, Cambridge, MA, USA) into each cell line, and 
after 24 and 48 hours, RNA was isolated.
Also, using the TransIT-X2® Dynamic Delivery System (MIR 6000; Cambridge Bioscience, UK), we trans-
fected repetitive synthetic double-stranded DNA sequences of poly(dA-dT)•poly(dT-dA) (Sigma-Aldrich, MO, 
USA) into each cell line at a dose of 0, 10, 100, 1000, or 10000 ng. RNA was isolated 24 and 48 hours thereafter. All 
experiments were performed independently three or more times.
Selection of candidate miRNAs targeting NOVA1 and transfection of miRNAs. Predicted target 
miRNA to NOVA1 were searched in a web-based database (http://www.microrna.org/microrna). We selected the 
first eight miRNAs with good support vector regression (SVR) values: miR-146a-5p, miR-146b-5p, miR-181a, 
miR-181b, miR-181c, miR-181d, miR-27a, and miR-27b.
Scrambled control miR (AccuTarget™ miRNA mimic Negative control; Bioneer, Daejeon, South Korea), 
hsa-miR-146b mimic (Bioneer), hsa-miR-146b-5p inhibitor (Bioneer), and hsa-miR-146b-3p inhibitor (Bioneer) 
were obtained and transfected at a concentration of 30 nM using the TransIT-X2® Dynamic Delivery System 
(MIR 6000; Cambridge). Co-transfection was performed with 100 ng of poly(dA:dT) and miR oligonucleotides 
of scramble miR, hsa-miR-146b mimic, hsa-miR-146b-5p inhibitor, or hsa-miR-146b-3p inhibitor. RNA was 
isolated after 24 hours of co-transfection. Experiments were performed independently three or more times.
RNA isolation and quantitative real-time PCR (qRT-PCR). RNA was isolated using RNeasy Plus Mini 
Kits (74134, Qiagen, Carlsbad, CA, USA), and cDNA was synthesized using cDNA synthesis kits (PB30.11 PCR 
Biosystems Ltd, Plymouth, PA, USA). Primers for HPV-16 E6, HPV-16 E7, TWIST, SNAI1, NOVA1, and GAPDH 
were manufactured (Integrated DNA Technologies, Coralville, IA, USA). The primer sequences are displayed in 
Supplementary Table S2. Using 2X qPCRBIO SyGreen Mix Lo-Rox (PB20.11 PCR Biosystems Ltd., Plymouth, PA, 
USA) as PCR reagent and the ABI 7500 Real-Time PCR System (Thermo Scientific, Logan, UT, USA), PCR was 
performed at 95 °C for 2 min; at 95 °C for 5 s and 60 °C for 30 s over 40 cycles; 95 °C for 15 s; 60 °C for 1 min; and 
95 °C for 15 s. Experiments were performed independently three or more times.
Quantification of miRNA in clinical samples of HNSCC. The expression patterns of candidate miR-
NAs in the microenvironment were analyzed in 50 FFPE specimens of HNSCC that were randomly selected and 
showed variable NOVA1 protein expression in tumor cells and stromal cells. Information on NOVA1 protein 
expression status in these 50 specimens is summarized in Supplementary Table S3. Tumor areas and surround-
ing stromal areas were separately dissected under a microscope. RNA, including microRNA, was isolated using 
miRNeasy FFPE Kits (Qiagen, Hilden, Germany). cDNA was synthesized using looped reverse transcription 
primers specific to individual miRNA species. Looped reverse transcription and forward and reverse primers 
for each microRNA species (hsa-miR-146a-5p, -146b-5p, -181a, -181b, -181c, -181d, -27a, and -27b, as well as 
a housekeeping gene, U6sn) are described in Supplementary Table S4. The expression of miRNA species was 
assayed quantitatively using a StepOnePlus Real-Time PCR instrument (Applied Biosystems, CA, USA) under 
the conditions of 94 °C for 2 min; 30 cycles of 94 °C for 15 s and 66 °C for 40 s; 94 °C for 15 s; 60 °C for 1 min; and 
94 °C for 15 s. All samples were analyzed twice to confirm reproducibility.
Immunohistochemistry and interpretation. Tissue microarray analysis was conducted by selecting two 
or three different tumor areas from 396 HNSCC samples. Core specimens 3 mm in diameter were obtained from 
donor tissue blocks and arranged in recipient TMA blocks using a trephine apparatus. Immunohistochemistry 
(IHC) was performed on 4-μm tissue microarray sections using a Ventana Bench Mark XT Autostainer (Ventana 
Medical Systems, Tucson, AZ, USA) and a LEICA BOND-III Autostainer (Leica Biosystems, Newcastle Upon 
Tyne, UK) according to the manufacturers’ protocols. The tested primary antibodies were as follows: p16 (RTU; 
Ventana), NOVA1 (1:500 dilution; Abcam, Cambridge, UK), CD3 (1:200 dilution; LabVision, Fremont, CA, 
USA), CD8 (RTU; clone C8/144B; Dako, Glostrup, Denmark), Twist (1:200 dilution; Abcam), and SNAI1/SLUG 
(1:200 dilution; Abcam).
Expression of NOVA1 was scored respectively in tumor cells, stromal spindle cells (fibroblasts, support cells, 
and endothelial cells), and immune cells (T lymphocytes) (Fig. 6). Nuclear expression of NOVA1, Twist, and 
SNAI1/SLUG were analyzed according to the semi-quantitative H-score method: this method yields a total score 
range of 0 to 30033, which is obtained by multiplying the dominant nuclear staining intensity score (0, no staining; 
1, weak or barely detectable nuclear staining; 2, distinct brown nuclear staining; 3, strong dark brown nuclear 
staining) by the percentage (0–100%) of positive cells. Densities of tumor infiltrating T lymphocytes (TILs) were 
semiquantitatively scored as follows28,34: the five most representative sections at high-power magnification (x400) 
were selected. Intact lymphocytes expressing CD3 and CD8 were counted manually, and the numbers of counted 
cells were averaged (Supplementary Fig. S10A,B). Conventionally accepted criteria for HPV-positivity were used 
for p16 IHC, and positivity was defined as the presence of strong and diffuse nuclear and cytoplasmic staining 
in >70% of the HNSCC cells. All other staining patterns were scored as negative (Supplementary Fig. S10C)35.
Gene expression profile analysis. Gene expression profiles with normalized RSEM values from the 
TCGA-HNSC cohort (https://cancergenome.nih.gov, n = 348) were downloaded using the TCGAbiolinks R 
package and were analyzed. Samples were classified into upper one-third and lower one-third sample groups 
according to expression levels of NOVA1. Immune and stromal cell abundance in individual specimens was 
calculated by the Microenvironment Cell Populations-counter (MCP-counter) R package36, and the Wilcoxon 
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Rank-Sum test was performed to determine differences in cell abundance between the two groups using R 
software.
Statistical analysis. The Mann-Whitney U test, one-way ANOVA, two-sample t-test, X2 test, and Pearson’s 
or Spearman’s correlation test were conducted to analyze the significance of differences among variables, as appro-
priate. Overall survival (OS) was measured from the date of surgery to the date of death or last follow-up visit. 
Progression-free survival (PFS) was measured from the date of initial diagnosis until disease progression, defined 
as cancer recurrence, continuance of progressive disease without complete remission, or cancer-related death, 
during the study period. Patient survival rates were determined using the Kaplan-Meier method, and differences 
in survival rates were compared using the log-rank test. Multivariate analysis was performed using the Cox pro-
portional hazards model. A two-sided p < 0.05 was considered statistically significant. Statistical analyses were 
performed using IBM SPSS 22 software for Windows (IBM Corp, Somers, New York).
Data Availability
The datasets used and/or analyzed in this study are available from the corresponding author upon reasonable 
request.
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